DE60326488D1 - Zusammensetzungen die eine kombination von diphenylharnstoff impdh-hemmern und apoptose-induzierenden antikrebsmitteln enthalten - Google Patents

Zusammensetzungen die eine kombination von diphenylharnstoff impdh-hemmern und apoptose-induzierenden antikrebsmitteln enthalten

Info

Publication number
DE60326488D1
DE60326488D1 DE60326488T DE60326488T DE60326488D1 DE 60326488 D1 DE60326488 D1 DE 60326488D1 DE 60326488 T DE60326488 T DE 60326488T DE 60326488 T DE60326488 T DE 60326488T DE 60326488 D1 DE60326488 D1 DE 60326488D1
Authority
DE
Germany
Prior art keywords
apoptosis
diphenyl
inductive
antibodies
heavy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60326488T
Other languages
German (de)
English (en)
Inventor
Jugnu Jain-Pandey
Robert J Fram
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60326488D1 publication Critical patent/DE60326488D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60326488T 2002-12-06 2003-12-04 Zusammensetzungen die eine kombination von diphenylharnstoff impdh-hemmern und apoptose-induzierenden antikrebsmitteln enthalten Expired - Lifetime DE60326488D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43155502P 2002-12-06 2002-12-06
US49626103P 2003-08-19 2003-08-19
PCT/US2003/038523 WO2004052349A2 (en) 2002-12-06 2003-12-04 Compositions comprising a combination of diphenyl ura impdh inhibitors and apoptosis-inducing anti-cancer agents

Publications (1)

Publication Number Publication Date
DE60326488D1 true DE60326488D1 (de) 2009-04-16

Family

ID=32511581

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60326488T Expired - Lifetime DE60326488D1 (de) 2002-12-06 2003-12-04 Zusammensetzungen die eine kombination von diphenylharnstoff impdh-hemmern und apoptose-induzierenden antikrebsmitteln enthalten

Country Status (8)

Country Link
US (1) US7943593B2 (enExample)
EP (1) EP1575579B1 (enExample)
JP (1) JP4789621B2 (enExample)
AT (1) ATE424198T1 (enExample)
AU (1) AU2003298868B2 (enExample)
CA (1) CA2510006C (enExample)
DE (1) DE60326488D1 (enExample)
WO (1) WO2004052349A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009505945A (ja) * 2005-05-26 2009-02-12 バーテックス ファーマシューティカルズ インコーポレイテッド （ｓ）−１−シアノブタン−２−イル（ｓ）−１−（３−（３−（３−メトキシ−４−（オキサゾール−５−イル）フェニル）ウレイド）フェニル）エチルカルバメートの多形形態
AU2020253560A1 (en) * 2019-04-05 2021-11-25 Prolynx Llc Improved conjugation linkers
JP2022136035A (ja) * 2021-03-04 2022-09-15 国立大学法人東京農工大学 化合物、該化合物を用いた金属ナノ粒子複合体、及び標的分子の検出方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210745A (en) * 1978-01-04 1980-07-01 The United States Of America As Represented By The Department Of Health, Education And Welfare Procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoroadenine
US4357324A (en) * 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
AU723730B2 (en) 1996-04-23 2000-09-07 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of IMPDH enzyme
CN1196687C (zh) * 1999-03-19 2005-04-13 沃泰克斯药物股份有限公司 Impdh酶抑制剂

Also Published As

Publication number Publication date
AU2003298868B2 (en) 2009-09-17
JP4789621B2 (ja) 2011-10-12
WO2004052349A3 (en) 2004-07-29
JP2006524186A (ja) 2006-10-26
AU2003298868A1 (en) 2004-06-30
US7943593B2 (en) 2011-05-17
ATE424198T1 (de) 2009-03-15
EP1575579B1 (en) 2009-03-04
WO2004052349A2 (en) 2004-06-24
EP1575579A2 (en) 2005-09-21
US20050059734A1 (en) 2005-03-17
CA2510006C (en) 2012-02-07
CA2510006A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
ATE372341T1 (de) Inhibitoren von mitotischem kinesin
ATE356804T1 (de) Inhibitoren von mitotischem kinesin
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
ATE447577T1 (de) Mitotische kinesin-hemmer
CR9465A (es) Compuestos mejorados farmacocineticamente
EP1551812A4 (en) MITOTIC KINESINE HEMMER
EP1515724A4 (en) MITOTIC KINESINE HEMMER
ATE448207T1 (de) Mitotische kinesin-hemmer
ATE421512T1 (de) Inhibitoren von mitotischem kinesin
CY1110498T1 (el) Παραγωγα πυραζολης ως αναστολεις των κινασων τυροσινης υποδοχεα
BRPI0407993B8 (pt) compostos inibidores de p38 e composições farmacêuticas compreendendo os mesmos
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
ATE481092T1 (de) Verfahren und zusammensetzungen zur apoptoseinduktion in krebszellen
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
ATE423087T1 (de) Proteasome inhibitoren und deren verwendung
DE602004020070D1 (de) Thienopyrimidin-derivate als kaliumkanal-inhibitoren
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
ATE443044T1 (de) Tace inhibitoren
DE60326488D1 (de) Zusammensetzungen die eine kombination von diphenylharnstoff impdh-hemmern und apoptose-induzierenden antikrebsmitteln enthalten
MX2021002995A (es) Inhibidores del inhibidor 1 de activador de plasminogeno (pai-1) y usos de los mismos.
ATE400812T1 (de) Zusammensetzungen und verfahren für verstärkte apoptose
ATE426605T1 (de) Inhibitoren von mitotischem kinesin
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
ATE435200T1 (de) Guanidinophenylalanin-verbindungen als urokinase- inhibitoren
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition